Across TCGA pan-cancer cohorts, UBE2D1 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated UBE2D1 data layer compared with 23 for mass-spec protein and 4 for mutation status.
The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher UBE2D1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated UBE2D1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.
LSCC and LUAD are the cancer types where UBE2D1 mass-spec protein most reproducibly stratifies survival.